Natco Pharma acquires Dash Pharma
New Delhi: Natco Pharma Inc. USA, a wholly owned subsidiary of NATCO Pharma Limited , has completed the acquisition of Dash Pharmaceuticals LLC, a New Jersey based entity.
Pursuant to this, Dash will become a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO.
The acquisition amount paid is US$ 18 million. Dash is a front-end pharmaceutical sales, marketing and distribution entity in the USA which is expected to have Net Sales of approximately USD 15 million for the financial year ending December 2021.
This acquisition provides NATCO with a platform to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.
Read also: Natco Pharma to acquire Dash Pharma
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.